Manuel Battegay
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
Wolbers M, Bucher H, Kaufmann G, Bernasconi E, Vernazza P, Hasse B, Cavassini M, Furrer H, Hirschel B, Battegay M, Swiss HIV Cohort Study. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral therapy 2007; 12:889-97.
01.01.2007CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy
01.01.2007Antiviral therapy 2007; 12:889-97
Wolbers Marcel, Bucher Heiner C, Kaufmann Gilbert, Bernasconi Enos, Vernazza Pietro, Hasse Barbara, Cavassini Matthias, Furrer Hansjakob, Hirschel Bernard, Battegay Manuel, Swiss HIV Cohort Study
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
Simcock M, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher H, Battegay M, Koller M, Moirandat-Rytz S, Terziroli B, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson J, Bernasconi E, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy 2007; 12:931-9.
01.01.2007Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
01.01.2007Antiviral therapy 2007; 12:931-9
Simcock Mathew, Furrer Hansjakob, Hirschel Bernard, Vernazza Pietro, Sendi Pedram, Rickenbach Martin, Bucher Heiner C, Battegay Manuel, Koller Michael T, Moirandat-Rytz Sophie, Terziroli Benedetta, Blasko Monika, Karrer Urs, Bertisch Barbara, Pless Miklos, Blumer Liisa, Vora Samir, Robinson James Owen, Bernasconi Enos, Swiss HIV Cohort Study
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
Glass T, Battegay M, Hirschel B, Cavassini M, Bernasconi E, Furrer H, Rickenbach M, Vernazza P, Weber R, De Geest S, Bucher H. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2006; 41:385-92.
01.03.2006Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study
01.03.2006Journal of acquired immune deficiency syndromes (1999) 2006; 41:385-92
Glass Tracy R, Battegay Manuel, Hirschel Bernard, Cavassini Matthias, Bernasconi Enos, Furrer Hansjakob, Rickenbach Martin, Vernazza Pietro, Weber Rainer, De Geest Sabina, Bucher Heiner C
A smoking cessation programme in HIV-infected individuals: a pilot study
Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher H, Spirig R, Battegay M, Swiss HIV Cohort Study. A smoking cessation programme in HIV-infected individuals: a pilot study. Antiviral therapy 2006; 11:787-95.
01.01.2006A smoking cessation programme in HIV-infected individuals: a pilot study
01.01.2006Antiviral therapy 2006; 11:787-95
Elzi Luigia, Spoerl David, Voggensperger Jacqueline, Nicca Dunja, Simcock Mathew, Bucher Heiner C, Spirig Rebecca, Battegay Manuel, Swiss HIV Cohort Study
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 2006; 11:131-42.
01.01.2006Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
01.01.2006Antiviral therapy 2006; 11:131-42
Zinkernagel Annelies S, Weber Rainer, Schmid Patrick, Bernasconi Enos, Opravil Milos, Tarr Philip E, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, Rickenbach Martin, Ledergerber Bruno, von Wyl Viktor, Swiss HIV Cohort Study
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
Karrer U, Speck R, Weber R, Russotti M, Schmid P, Hirschel B, Gayet-Ageron A, Cavassini M, Battegay M, Elzi L, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS (London, England) 2005; 19:1987-94.
18.11.2005Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
18.11.2005AIDS (London, England) 2005; 19:1987-94
Karrer Urs, Speck Roberto F, Weber Rainer, Russotti Marina, Schmid Patrick, Hirschel Bernard, Gayet-Ageron Angèle, Cavassini Matthias, Battegay Manuel, Elzi Luigia, Furrer Hansjakob, Ledergerber Bruno, Swiss HIV Cohort Study
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
01.11.2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
01.11.2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study
[Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]
Nicca D, Fehr J, Battegay M, Spirig R. [Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]. Pflege 2005; 18:289-98.
01.10.2005[Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV]
01.10.2005Pflege 2005; 18:289-98
Nicca Dunja, Fehr Jan, Battegay Manuel, Spirig Rebecca
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72.
01.08.2005Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
01.08.2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Perrin Luc, Ledergerber Bruno, Furrer Hansjakob, Swiss HIV Cohort Study
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. The Journal of infectious diseases 2005; 191:1419-26.
01.05.2005Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
01.05.2005The Journal of infectious diseases 2005; 191:1419-26
Tarr Philip E, Telenti Amalio, Ledergerber Bruno, Rickenbach Martin, Darioli Roger, Bernasconi Enos, Vernazza Pietro, Weber Rainer, Battegay Manuel, Hirschel Bernard, Martinez Raquel, Rotger Margalida, Furrer Hansjakob, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Weber R, Rickenbach M, Bucher H. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral therapy 2005; 10:73-81.
01.01.2005Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study
01.01.2005Antiviral therapy 2005; 10:73-81
Young Jim, Battegay Manuel, Vernazza Pietro, Tarr Philip E, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Weber Rainer, Rickenbach Martin, Bucher Heiner C
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
Young J, Battegay M, Vernazza P, Tarr P, Hirschel B, Bernasconi E, Furrer H, Rickenbach M, Weber R, Bucher H. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antiviral therapy 2005; 10:585-91.
01.01.2005Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study
01.01.2005Antiviral therapy 2005; 10:585-91
Young Jim, Battegay Manuel, Vernazza Pietro, Tarr Philip E, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Rickenbach Martin, Weber Rainer, Bucher Heiner C
Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Fehr J, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Battegay M. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33:249-256.
01.01.2005Starting or changing therapy - a prospective study exploring antiretroviral decision-making
01.01.2005Infection 2005; 33:249-256
Fehr Jan, Spirig R, Jäger H, Vernazza Pietro, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca Dunja, Battegay Manuel
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
Trkola A, Günthard H, Bonhoeffer S, Hirschel B, Weber R, Bernasconi E, Vernazza P, Battegay M, Furrer H, Fagard C, Oxenius A, Leemann C, Kuster H, Swiss HIV Cohort Study. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-92.
15.09.2004Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
15.09.2004Blood 2004; 104:1784-92
Trkola Alexandra, Günthard Huldrych F, Bonhoeffer Sebastian, Hirschel Bernard, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Furrer Hansjakob, Fagard Catherine, Oxenius Annette, Leemann Christine, Kuster Herbert, Swiss HIV Cohort Study
Is unsafe sexual behaviour increasing among HIV-infected individuals?
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Weber R, Rickenbach M, Vernazza P, Young J, Swiss HIV Cohort Study. Is unsafe sexual behaviour increasing among HIV-infected individuals?. AIDS (London, England) 2004; 18:1707-14.
20.08.2004Is unsafe sexual behaviour increasing among HIV-infected individuals?
20.08.2004AIDS (London, England) 2004; 18:1707-14
Glass Tracy R, Bucher Heiner C, Battegay Manuel, Hirschel Bernard, Cavassini Matthias, Weber Rainer, Rickenbach Martin, Vernazza Pietro, Young Jim, Swiss HIV Cohort Study
Gynecomastia and potent antiretroviral therapy
Strub C, Kaufmann G, Flepp M, Egger M, Kahlert C, Cavassini M, Battegay M. Gynecomastia and potent antiretroviral therapy. AIDS (London, England) 2004; 18:1347-9.
18.06.2004Gynecomastia and potent antiretroviral therapy
18.06.2004AIDS (London, England) 2004; 18:1347-9
Strub Christoph, Kaufmann Gilbert R, Flepp Markus, Egger Martin, Kahlert Christian, Cavassini Matthias, Battegay Manuel
The decision to get vaccinated against influenza
Sendi P, Locher R, Bucheli B, Battegay M. The decision to get vaccinated against influenza. Am J Med 2004; 116:856-8.
15.06.2004The decision to get vaccinated against influenza
15.06.2004Am J Med 2004; 116:856-8
Sendi Pedram, Locher Rebecca, Bucheli Bruno, Battegay Manuel
Infrequent transmission of HIV-1 drug-resistant variants
Yerly S, Perrin L, Hirschel B, Perneger T, Bernard M, Gebhardt M, Rickenbach M, Bürgisser P, Chanzy B, Furrer H, Battegay M, Vernazza P, Chave J, Kaiser L, Flepp M, Telenti A, Jost S, Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. Antiviral therapy 2004; 9:375-84.
01.06.2004Infrequent transmission of HIV-1 drug-resistant variants
01.06.2004Antiviral therapy 2004; 9:375-84
Yerly Sabine, Perrin Luc, Hirschel Bernard, Perneger Thomas, Bernard Marie-Charlotte, Gebhardt Martin, Rickenbach Martin, Bürgisser Philippe, Chanzy Bruno, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Chave Jean-Philippe, Kaiser Laurent, Flepp Markus, Telenti Amalio, Jost Stéphanie, Swiss HIV Cohort Study
Sexual risk behavior in HIV-infected injection drug users
Battegay M, Bucher H, Vernazza P. Sexual risk behavior in HIV-infected injection drug users. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004; 38:1175-7.
15.04.2004Sexual risk behavior in HIV-infected injection drug users
15.04.2004Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004; 38:1175-7
Battegay Manuel, Bucher Heiner C, Vernazza Pietro
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Cavassini M, Furrer H, Perrin L, Weber R, Khanna N, Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antiviral therapy 2004; 9:263-74.
01.04.2004Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
01.04.2004Antiviral therapy 2004; 9:263-74
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Ledergerber Bruno, Cavassini Matthias, Furrer Hansjakob, Perrin Luc, Weber Rainer, Khanna Nina, Swiss HIV Cohort Study